Emerging Data on the Safety and Efficacy of Transurethral Water Vapour Therapy for Benign Prostatic Hyperplasia

Juliebø‐Jones, Patrick; Siena, Giampaolo; Hameed, B. M. Zeeshan; Somani, Bhaskar K.

doi:10.2147/rru.s273686

Cited by 3 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another caution when using reintervention following water vapour therapy in patients with prior Urolift is the theoretical possibility of loosening of the preplaced clips as the prostatic tissue undergoes apoptosis and resorption after vapour therapy (Jones et al, 2021). In our 3 month follow up we did not encounter complication due to the clips subsequent migration.…”

Section: Discussionmentioning

confidence: 70%

“…Hence, extra care must be maintained to ensure that vapour injections are placed only as per the original description to prevent any sphincter damage and subsequent incontinence (McVary et al, 2016). Another caution when using reintervention following water vapour therapy in patients with prior Urolift is the theoretical possibility of loosening of the preplaced clips as the prostatic tissue undergoes apoptosis and resorption after vapour therapy (Jones et al, 2021). In our 3 month follow up we did not encounter complication due to the clips subsequent migration.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Rezum to the rescue: Early outcomes of Rezum on patients with recurrent lower urinary tract symptoms after surgical interventions for benign prostatic enlargement

et al. 2022

View full text Add to dashboard Cite

We aim to report the short-term outcomes of patients undergoing Rezum as a retreatment intervention for recurrent lower urinary tract symptoms after prior surgical treatment for benign prostate enlargement. Data from two institutions for baseline International Prostatic Symptom Score with Quality of life item, prostate size, and maximum flow-rate was acquired. Patients were assessed 3-month post-treatment. Outcomes were compared with unpaired t-tests and Fisher's exact tests. Nineteen patients were included. Prior surgical interventions included transurethral resection of the prostate (31.6%, n = 6), Urolift (26.3%, n = 5), transurethral bladder neck incision (15.8%, n = 3), prostate artery embolization (10.5%, n = 2), transurethral needle ablation, greenlight photovaporization of prostate and Rezum (5.3%, n = 1 each). Median age was 69.0 years (IQR 14; range 59-87 years) with a median prostate volume of 65.0 ml (IQR 63; range 22-160 ml). The median time to Rezum treatment was 48 months (IQR 78; range 9-240 months). 63.1% (n = 12) were re-started on benign

show abstract

Section: Discussionmentioning

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Rezum to the rescue: Early outcomes of Rezum on patients with recurrent lower urinary tract symptoms after surgical interventions for benign prostatic enlargement

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In addition, the procedure has a lower incidence of sexual side effects compared with other treatments. Preservation of sexual function is a major concern for many patients, and Rezum therapy has been shown to have a lower incidence of sexual side effects compared with HoLEP, TURP, greenlight, and other surgical interventions [11] .…”

Section: Side Effects and Conclusionmentioning

confidence: 99%

Rezum: a novel transurethral water vapor therapy for benign prostatic hyperplasia

Nadeem¹,

Ahsan²,

Tariq³

et al. 2023

International Journal of Surgery: Global Health

View full text Add to dashboard Cite

BackgroundBenign prostatic hyperplasia (BPH) is a condition in which the prostate gland enlarges and is mostly observed in men over 50 years of age. It is characterized by glandular proliferation resulting in prostatic hyperplasia. Lower urinary tract symptoms suggestive of BPH include urinary frequency, urgency, trouble starting a urine stream, a weak or interrupted urine stream, dribbling at the end of urination, nocturia, and urinary retention [1] . BPH is not cancerous but if left untreated, it can lead to urinary tract infections, bladder and kidney damage, and eventually death. Throughout the past 3 decades, there has been a significant decline in mortality rates for deaths linked to BPH. This is probably due to advances in the standard of care provided to patients with the condition [2] .A variety of tests are available to diagnose BPH including digital rectal examination, urinalysis, prostate-specific antigen blood test, urodynamic tests including uroflowmetry, postvoid residual measurement, and reduced urine flow. Other advance diagnostic tools include cystoscopy, transrectal ultrasound, and biopsy. Advantages of Rezum therapyRezum therapy has the advantage of being a relatively quick procedure. It typically takes less than an hour to complete. The

show abstract

“…Therefore, there is urgent need innovative treatment options, especially non-invasive or minimal invasive, effective, safe, and economical theapies. Radiofrequency (RF) therapy and treatment have these characteristics with many fields of application in surgery and medicine ( 13 , 14 ). It has been applied to a variety of diseases as an economical, efficient and minimally invasive treatment option with high compliance ( 15 ).…”

Section: Introductionmentioning

confidence: 99%

A Multi-Center, Randomized, Blind, Controlled Clinical Trial of the Safety and Efficacy of Micro Radio Frequency Therapy System for the Treatment of Overactive Bladder

Zhang

Wang

et al. 2022

Front. Med.

View full text Add to dashboard Cite

PurposeThe purpose of this study was to evaluate the efficacy and safety of low power micro radiofrequency (RF) therapy (μRFthera®) through urethra in the treatment of overactive bladders (OAB) through a prospective, single-blind, placebo-controlled, multi-center clinical protocol.Materials and MethodsOne hundred and fourteen patients with refractory OAB were randomized at 2:1 ratio, treatment to control undergoing same procedures except only the micro-RF treatment group at turned “on” setting in energy. Bladder diaries recorded during the screening period (3 days before enrollment) and during follow-up period on week 1, 3, and 7, respectively. The patients in control could choose receiving an energized treatment during extension stage.ResultsThe treatment efficacy was 76.1%. There was 49.80% rate improvement compared to control (95%CL 32.48%, 67.13%). The crude rate ration (RR) was 2.89, 95% CI (1.67–5.01) with p < 0.001 in uni-variate analysis, while the RR became 2.94, 95% CI (1.67–5.16) with p < 0.001 after adjusted potential confounding factors in multi-variate analysis. Statistically significant improvements have been demonstrated in the frequency of urination, urgency, nocturia, and quality of life (QoL) scores.ConclusionsMicro RF therapy is safe and effective for the treatment of OAB. The main treatment-related complications were catheterization related complications.Clinical Trial RegistrationZhejiang Device Registration Certificate No. 202090909, www.chictr.org.cn, Clinical Trial Accession Number: ChiCTR2100050096.

show abstract

Emerging Data on the Safety and Efficacy of Transurethral Water Vapour Therapy for Benign Prostatic Hyperplasia

Cited by 3 publications

References 24 publications

Rezum to the rescue: Early outcomes of Rezum on patients with recurrent lower urinary tract symptoms after surgical interventions for benign prostatic enlargement

Rezum to the rescue: Early outcomes of Rezum on patients with recurrent lower urinary tract symptoms after surgical interventions for benign prostatic enlargement

Rezum: a novel transurethral water vapor therapy for benign prostatic hyperplasia

A Multi-Center, Randomized, Blind, Controlled Clinical Trial of the Safety and Efficacy of Micro Radio Frequency Therapy System for the Treatment of Overactive Bladder

Contact Info

Product

Resources

About